The patent covers the claims related to application No.12/769,885 for the use of Amarin’s product, Vascepa (icosapent ethyl) capsules, as a treatment for hypertriglyceridemia.
Amarin chairman and chief executive officer Joseph Zakrzewski said the patent issuance represents another step forward in the company’s effort to protect the commercial potential of Vascepa.
"Amarin’s goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry," Zakrzewski added.
In addition, the company is pursuing patent applications related to Vascepa in multiple jurisdictions outside the US, including the application for Amarin’s MARINE method of use patent in Europe, for which it has announced receipt of an Intention to Grant letter.